Posted: Aug 4, 2016
Highthroughput screening uncovers molecular targets for treatment.
Posted: Jul 28, 2016
New Technology Precisely Measures DNA Breaks In Vivo: An Interview with CCR’s Andre Nussenzweig
Posted: Jul 27, 2016
Results from a pilot clinical trial found that TARP, or T-cell receptor gamma chain alternate reading frame protein, vaccination slowed prostate-specific antigen (PSA) rise in the majority of patients with early stage prostate cancer.
Posted: Jul 27, 2016
Watch Dr. Ira Pastan explain his recently published research on the next generation of immunotoxins targeting mesothelin
Posted: Jul 20, 2016
A study by a team of CCR investigators has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Posted: Jul 7, 2016
The glucocorticoid receptor (GR) is a ligand-regulated transcription factor and one of the most targeted proteins in the pharmaceutical industry due to its powerful antiinflammatory actions. The search for side effects-free glucocorticoids relies exclusively on a model wherein the GR oligomerization state, whether a monomer or a dimer, dictates its transcriptional output. Here, Dr. Gordon Hager, Dr. Diego Presman, and colleagues use an experimental approach where the GR–DNA interaction is observed in real time with a technique that allows the quantification of the oligomeric state of proteins in living cells. Unexpectedly, they find that DNA binding triggers tetramerization of the GR, which would be the truly activated form of the receptor. Their findings reveal a previously unidentified step in the glucocorticoid activation pathway.
Posted: Jun 28, 2016
CCR investigators are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma. are using circulating tumor DNA (ctDNA) as a type of noninvasive liquid biopsy for patients with diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.
Posted: Jun 27, 2016
Drs. Peter Choyke (Molecular Imaging Program, CCR) and Stacy Loeb (New York University Langone Medical Center) talk to CancerNetwork about the progress that has been made in active surveillance for prostate cancer.